About this trial

This study aims to investigate the methylomic features of patients with hepatitis B-related acute-on-chronic liver failure and establish and validate a prognostic risk prediction classification model. The findings are of significant importance for guiding clinical practice and improving patient prognosis. Additionally, a methylomics-based classifier model for liver failure will be developed for disease prognosis analysis and clinical assessment, with the potential to enhance the diagnostic efficiency of liver failure.

Eligibility criteria

Qualifiers

Chronic hepatitis B was persistent hepatitis B surface antigen (HBsAg) seropositivity for more than six months.

Disqualifiers

co-infection with other hepatitis viruses; history of hepatocellular carcinoma or other malignancies; concomitant autoimmune liver disease; or insufficient clinical data.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

100 Participants
are grouped into 3 trial groups

Locations

1
Qilu Hospital of Shandong University250012, JinanShandong, China

Sponsors and collaborators

Qilu Hospital of Shandong University

Lead sponsor